CINECA IRIS Institutional Research Information System

GRAGNANI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.926
NA - Nord America 3.696
EU - Europa 2.210
SA - Sud America 459
Continente sconosciuto - Info sul continente non disponibili 312
AF - Africa 110
OC - Oceania 2
Totale 10.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.557
IT - Italia 1.389
SG - Singapore 1.248
CN - Cina 1.146
HK - Hong Kong 582
BR - Brasile 369
KR - Corea 288
VN - Vietnam 180
IN - India 139
SE - Svezia 130
DE - Germania 115
GB - Regno Unito 112
JP - Giappone 110
FR - Francia 95
CH - Svizzera 78
FI - Finlandia 74
RU - Federazione Russa 64
CA - Canada 56
BD - Bangladesh 38
ZA - Sudafrica 34
MX - Messico 33
IQ - Iraq 32
AR - Argentina 30
TR - Turchia 29
PL - Polonia 28
CI - Costa d'Avorio 26
AT - Austria 24
NL - Olanda 20
SA - Arabia Saudita 20
BG - Bulgaria 15
UA - Ucraina 15
PK - Pakistan 14
VE - Venezuela 13
CO - Colombia 12
CZ - Repubblica Ceca 12
UZ - Uzbekistan 12
JO - Giordania 11
CL - Cile 10
ES - Italia 10
JM - Giamaica 10
KE - Kenya 10
PH - Filippine 9
MA - Marocco 8
BB - Barbados 7
EC - Ecuador 7
IE - Irlanda 7
NP - Nepal 7
TW - Taiwan 7
CR - Costa Rica 6
EG - Egitto 6
GT - Guatemala 6
HN - Honduras 6
ID - Indonesia 6
PS - Palestinian Territory 5
PY - Paraguay 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
IL - Israele 4
SN - Senegal 4
TH - Thailandia 4
AO - Angola 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
ET - Etiopia 3
GR - Grecia 3
IR - Iran 3
MY - Malesia 3
OM - Oman 3
PE - Perù 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AU - Australia 2
BH - Bahrain 2
BO - Bolivia 2
CG - Congo 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LT - Lituania 2
LY - Libia 2
NG - Nigeria 2
PA - Panama 2
SR - Suriname 2
SV - El Salvador 2
TJ - Tagikistan 2
AL - Albania 1
AW - Aruba 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BS - Bahamas 1
EU - Europa 1
GH - Ghana 1
Totale 10.392
Salva come PNG Salva come JPEG
Città #
Milan 797
Singapore 736
Hong Kong 572
Ashburn 500
San Jose 487
Hefei 476
Santa Clara 442
Seoul 286
Shanghai 245
Council Bluffs 244
Dallas 166
Boardman 165
New York 131
Pisa 127
Tokyo 106
Los Angeles 103
Rome 94
Beijing 83
Bern 72
Hyderabad 63
Fairfield 58
Helsinki 56
Ho Chi Minh City 55
Lauterbourg 55
London 50
Florence 49
Seattle 46
Hanoi 43
Frankfurt am Main 40
Chicago 37
Munich 35
Buffalo 32
Woodbridge 32
Phoenix 31
Redondo Beach 31
São Paulo 30
Abidjan 26
Warsaw 26
Houston 24
Wilmington 21
Nuremberg 18
Serra 16
Cambridge 15
Chandler 15
Ann Arbor 14
Johannesburg 14
Rio de Janeiro 14
Istanbul 13
Sofia 13
Atlanta 12
Baltimore 12
Brooklyn 12
Tashkent 12
Amman 11
Turku 11
Chennai 10
Da Nang 10
Elk Grove Village 10
Fuzhou 10
Mexico City 10
Montreal 10
San Francisco 10
Belo Horizonte 9
Cape Town 9
Dhaka 9
Falkenstein 9
Baghdad 8
Brasília 8
Brno 8
Lucknow 8
Nairobi 8
Orem 8
Philadelphia 8
Pune 8
Vienna 8
Bridgetown 7
Dublin 7
Mumbai 7
North Bergen 7
Ottawa 7
Riyadh 7
Salt Lake City 7
Tampa 7
Toronto 7
Bogotá 6
Columbus 6
Erbil 6
Guatemala City 6
Hải Dương 6
Lawrence 6
Porto Alegre 6
San Giuliano Terme 6
Washington 6
Zhengzhou 6
Boston 5
Brookline 5
Cairo 5
Dammam 5
Des Moines 5
Durban 5
Totale 7.205
Salva come PNG Salva come JPEG
Nome #
HBV and HCV testing outcomes among marginalized communities in Italy, 2019–2024: a prospective study 253
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma 218
Thyroid Autoimmunity and SARS-CoV-2 Infection 167
Mixed cryoglobulinemia syndrome is a negative prognostic factor in the standard of care (Peg-IFN+ribavirin) anti-HCV therapy 159
IgG cryoglobulinemia 159
Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis 156
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement 154
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 152
A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort 151
COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity 149
Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? 144
Interferon-free therapy in hepatitis C virus mixed cryoglobulinaemia: a prospective, controlled, clinical and quality of life analysis 142
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 142
Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study 137
Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection 137
Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment 136
A serum metabolomic analysis of HCV-infected patients successfully treated with IFN-free DAA regimens 136
HCV-related rheumatic manifestations and therapeutic strategies 136
Different biochemical patterns in type II and type III mixed cryoglobulinemia in HCV positive patients 134
Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral sustained viral response (SVR) after antiviral therapy 132
Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia 131
P0752 : NOTCH4 and MHC class II polymorphisms contibute to HCV-related benign and malignant lymphoproliferative diseases 131
Detection of WA B Cells in HCV Infection by Molecular Analysis: A Prognostic Marker for Cryoglobulinemic Vasculits and B Cell Lymphomas 130
Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection 130
Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26 129
Could the presence of Mixed Cryoglobulinemia influence the outcome of standard peg-IFN plus ribavirin anti-HCV therapy? 129
Autoimmunity and lymphoproliferation markers in naïve HCV-RNA positive patients without clinical evidences of autoimmune/lymphoproliferative disorders 129
The Hepatitis C Virus Infection as a Systemic Disease 128
MicroRNA expression in hepatitis C virus-related malignancies: A brief review 128
HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1 127
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment 126
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 126
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study 126
Treatment of HCV-related mixed cryoglobulinemia 126
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 126
Combined treatment with antiviral therapy and rituximab in patients with mixed cryoglobulinemia: review of the literature and report of a case using direct antiviral agents-based antihepatitis C virus therapy 125
Host genetic determinants in HCV-related mixed cryoglobulinemia 124
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 124
Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study 123
HCV and lymphoproliferation 123
microRNA PROFILE MODIFICATIONS IN HEPATITIS C VIRUS-RELATED MIXED CRYOGLOBULINEMIA 122
Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection 121
HCV infection, malignancy and liver transplantation 119
Bcl-2 rearranged B cell clones in chronic HCV infection: a possible factor negatively influencing the virological response to treatment 118
Genetic determinants in Hepatitis C Virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc-gamma receptors 116
NOTCH4 AND MHC CLASS II POLYMORPHISMS CONTRIBUTE TO HCV-RELATED BENIGN AND MALIGNANT LYMPHOPROLIFERATIVE DISEASES 116
Plasma PAF-AH biological activity decreases in patients with HCV chronic infection 114
Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? 113
Thyroid autoimmunity and SARS-CoV-2 infection: Report of a large Italian series 113
Non-Invasive B-Cell Clonality Markers May Help in the Rational Approach to HCV Svr Cryoglobulinemic Patients with Persisting Manifestations 110
HCV-related lymphatic and hepatic malignancies are associated with different microRNA expression patterns in PBMCs 109
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 107
Opposite Effects of mRNA-Based and Adenovirus-Vectored SARS-CoV-2 Vaccines on Regulatory T Cells: A Pilot Study 107
Role of notch receptors in hematologic malignancies 104
HCV AND lymphoma: Genetic and epigenetic factors 100
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 92
Regression of t(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 92
Assessment of Free Light Chains in HCV positive patients undergoing Rituximab treatment 88
IL28B POLYMORPHISM AS PREDICTOR OF RESPONSE TO ANTI-HCV THERAPY IN HCV-RELATED MIXED CRYOGLOBULINEMIA SYNDROME 88
Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis 86
High prevalence of past hepatitis B virus infection in diffuse large B cell lymphoma: a retrospective study from Italy 82
Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: A review of the literature 75
DNA Damage Response Protein CHK2 Regulates Metabolism in Liver Cancer 75
MIR-17/92 EXPRESSION PATTERN: A MOLECULAR SIGNATURE OF HCV-RELATED MIXED CRYOGLOBULINEMIA 75
null 74
Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia 72
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 72
Host genetic determinants in HCV-related mixed cryoglobulinemia 71
COVID-19 AND CRYOGLOBULINEMIC VASCULITIS. LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION 69
Hepatitis C virus-associated B-cell lymphomas: The importance of the new direct antiviral agent therapy 67
Hepatitis C virus lymphotrophism: lessons from a decade of studies 67
Evaluation of Plasma miR-17-5p, miR-24-3p and miRNA-223-3p Profile of Hepatitis C Virus-Infected Patients after Treatment with Direct-Acting Antivirals 65
Modifications of plasma platelet-activating factor (PAF)- acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection 63
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies 62
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study 62
Free light chains: Eclectic multipurpose biomarker 59
Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis 57
Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia 56
Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: Preliminary results of a prospective pilot study 56
Hepatitis b virus-related cryoglobulinemic vasculitis: Review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the italian study group of cryoglobulinemia (gisc) 54
HCV-related cryoglobulinemic vasculitis (mixed cryoglobulinemia syndrome) in the era of direct-acting antivirals: A 10-year experience from Italian tertiary referral centers 51
Fibrosis assessment in patients with HCV or HBV chronic infection 50
KDM2A chromatin regulator constrains senescence program and immunoresponse in liver cancer 48
Exploratory study of extracellular matrix biomarkers for non-invasive liver fibrosis staging: A machine learning approach with XGBoost and explainable AI 46
Response to IFN-based antiviral therapy and long term effect of HCV eradication in Mixed Cryoglobulinemia, with or without symptoms: a prospective, controlled, open-label, long term, cohort study 46
Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life 44
A stereotyped light chain may shape virus-specific B-cell receptors in HCV-dependent lymphoproliferative disorders 44
Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression 43
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 43
HBV and HCV screening and linkage-to-care in vulnerable people permanently or temporarily living in Tuscany 42
Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment 42
The Key Importance of Screening Underprivileged People in Order to Achieve Global Hepatitis Virus Elimination Targets 42
HIGH SVR RATES WITH SMV plus SOF IN HCV GT1 AND GT4 PATIENTS WITH CIRRHOSIS OR ADVANCED FIBROSIS: A REAL PRACTICE ANALYSIS FROM A LARGE REGIONAL DATABASE IN TUSCANY, ITALY 41
Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies 41
Regression of T(14;18) bearing B-cell clones following antiviral therapy in chronic HCV infection 41
Early decrease of T-bet+ B cells during subcutaneous belimumab predicts response to therapy in systemic lupus erythematosus patients 40
Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia 36
The Relevance of MicroRNAs in the Pathogenesis and Prognosis of HCV-Disease: The Emergent Role of miR-17-92 in Cryoglobulinemic Vasculitis 34
Presence of BCL-2 rearranged B-cell clones in chronic HCV infection may negatively influence virological response to treatment 34
Effect of chronic hepatitis C virus infection on inflammatory lipid mediators 34
Totale 9.945
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202269 0 0 0 4 8 15 1 6 2 12 5 16
2022/2023449 8 6 10 4 4 11 257 19 87 11 23 9
2023/20241.613 277 230 325 178 248 134 20 26 5 22 12 136
2024/20253.658 126 134 40 122 323 238 249 120 304 322 548 1.132
2025/20263.537 248 608 304 306 410 231 557 157 249 246 95 126
2026/20271.146 128 385 562 71 0 0 0 0 0 0 0 0
Totale 10.715